~~<i id='AD30379737'><strike id='AD30379737'><tt id='AD30379737'><pre id='AD30379737'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：focus 2025-09-29 23:27:14 Page View：1731

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： NASA releases new images of 'fingerprint
Next article： Supreme Court strikes down use of affirmative action

focus

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

BraziliansoccerplayerNeymarwatchesduringthefirsthalfofGame4ofthebasketballNBAFinalsbetweentheMiamiHe

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Eating disorder hotline's move to chatbot carried cost for volunteers

AdobeEarlythisspring,dozensofvolunteersfieldingrequestsfrompeoplestrugglingwitheatingdisorders—manyo

WSS

explore

explore

comprehensive

focus

Eating disorder hotline's move to chatbot carried cost for volunteers